Answers are grounded in this paper and cite their sources.
Tobacco consumption remains a leading avoidable cause of death. This viewpoint reviews how Swiss public health organisations mobilised against the IQOS heated tobacco product developed by Philip Morris International. The mobilisation focused on a proposed 2016 “flagship store” in Lausanne (Switzerland), which catalysed coordinated action. Switzerland’s comparatively weak tobacco control regulations made it an early test market for IQOS from 2015. The Swiss market also offered favourable conditions for IQOS testing and promotion due to the product’s development in Switzerland, high purchasing power, and the valorisation of Swiss innovation. It also enabled the industry to exploit regulatory loopholes, such as weaker warnings, lower taxation, and an unclear second-hand smoke exposure ban. This exemplifies how industries exploit scientific uncertainty, definitional gaps, and political influence to circumvent, weaken, and delay regulation, allowing new products time to establish a market presence and shape public perceptions before effective controls are implemented. When Philip Morris International proposed a large experiential store combining retail, exhibition space, and a restaurant, advocates perceived it as an attempt to renormalise tobacco. A multisectoral response combined political monitoring, engagement with authorities, independent aerosol testing, and collective legal opposition. This response led to parliamentary scrutiny and a construction permit that forbade indoor use of heated tobacco, except in enclosed smoking rooms. Philip Morris eventually abandoned the flagship project in 2018. In 2019, it adapted by opening a smaller outlet. This experience highlights several key lessons: industry innovation exploits regulatory loopholes; robust, anticipatory laws and enforcement are essential; independent research is critical for countering industry influence and narratives; and large coalitions strengthen public health influence. Since 2024, the Swiss Tobacco Products Act has expanded regulations to all nicotine products and restricted advertising. Sustained, evidence-based advocacy is needed to combat the commercial determinants of health and prevent the industry from promoting harmful products.
No takes yet. Share an insight, caveat, or question.
Ballmer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: